Huawei Watch Reportedly Detects Pre-Symptomatic Diabetes Risk
Huawei has launched its Watch GT 6 Pro, which can reportedly detect diabetes risk through non-invasive monitoring before clinical symptoms appear. The development marks a significant step in embedded health sensing for wearables, potentially moving beyond fitness tracking into preventative diagnostics. The device's launch in Dubai positions it ahead of competitors like Apple and Samsung in the race for non-invasive glucose monitoring.
- The risk assessment relies on photoplethysmography (PPG), the same optical sensor technology used for heart rate and blood oxygen monitoring, to analyze blood flow characteristics over a 3 to 14-day period. It does not provide a quantitative blood glucose reading but categorizes risk as low, medium, or high to prompt medical consultation. - Huawei's earlier Watch 4 series included a hyperglycemia alert feature that analyzed 10 health indicators, including heart rate and pulse wave characteristics, after seven days of continuous wear. This required users in China to enroll in a third-party medical research program. - Competitor Apple has been pursuing non-invasive glucose monitoring for over a decade, reportedly developing a silicon photonics chip that uses optical absorption spectroscopy to measure glucose in interstitial fluid. While a proof-of-concept exists, the hardware is currently the size of an iPhone and is considered many years from being integrated into an Apple Watch. - Samsung has also publicly stated it is developing a non-invasive, optically-based continuous glucose monitor for its Galaxy Watch line, with a senior vice president, Dr. Hon Pak, acknowledging the project's progress without providing a launch timeline. - The U.S. Food and Drug Administration (FDA) has not authorized or approved any smartwatch or smart ring to measure blood glucose levels on its own. The agency has issued a safety communication warning consumers against using such devices for managing diabetes. - Current FDA-cleared smartwatch integration relies on displaying data from Continuous Glucose Monitors (CGMs), like the Dexcom G7, which use a separate, minimally invasive sensor to pierce the skin and measure glucose levels. - The feature was announced at the World Health Expo 2026 in Dubai and is being validated in a clinical study with 150 patients in the region. Huawei explicitly states the function is not a medical device and is intended for wellness awareness, not clinical diagnosis.
